CU-CPT4a
CU-CPT4a is a drug which acts as a selective antagonist of Toll-like receptor 3 (TLR3), with an IC50 of 3.44 μM. It is used for research into the function of TRL3 and its role in inflammation, autoimmune disorders and cancer.[1][2]
![]() | |
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
ChEMBL | |
Chemical and physical data | |
Formula | C18H13ClFNO3S |
Molar mass | 377.81 g·mol−1 |
3D model (JSmol) | |
| |
|
See also
References
- Martin-Gayo E, Cole MB, Kolb KE, Ouyang Z, Cronin J, Kazer SW, et al. (January 2018). "A Reproducibility-Based Computational Framework Identifies an Inducible, Enhanced Antiviral State in Dendritic Cells from HIV-1 Elite Controllers". Genome Biology. 19 (1): 10. doi:10.1186/s13059-017-1385-x. PMID 29378643.
- Lomphithak T, Choksi S, Mutirangura A, Tohtong R, Tencomnao T, Usubuchi H, Unno M, Sasano H, Jitkaew S (October 2020). "Receptor-interacting protein kinase 1 is a key mediator in TLR3 ligand and Smac mimetic-induced cell death and suppresses TLR3 ligand-promoted invasion in cholangiocarcinoma". Cell Communication and Signaling : CCS. 18 (1): 161. doi:10.1186/s12964-020-00661-3. PMC 7545934. PMID 33036630.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.